‼️ BREAKING: Eli Lilly easily tops quarterly estimates, raises outlook as Zepbound and Mounjaro sales surge. Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from a previous guidance of $82 billion to $85 billion. Lilly projects its full-year adjusted profit to be between $35.50 and $36.50 per share, which compares with a previous outlook of $35.50 to $37 per share.
AlgoTrader 